A research team at Howard Hughes Medical Institute headed by Brian J. Druker has developed, in pursuit of personalized medicine, a new technique in identifying previously unknown genetic mutations that trigger growth of cancer cells.
Inside cells of acute myeloid leukemia (AML), the researchers have dramatically reduced the time it takes to pinpoint molecular abnormalities that might be vulnerable to specific drug treatments by analyzing the proteins instead of the genes.
“This approach gives us a way to figure out what’s driving the growth of a cancer in an individual patient and ultimately match that patient with the right drug,” said Druker, …read more